CSL’s ‘big’ post-heart attack drug fails in Phase III trial
CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of major adverse cardiovascular events.
CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of major adverse cardiovascular events.
What's Your Reaction?
